Burden of bisphosphonate-associated femoral fractures

ANZ Journal of Surgery

Volumn 83, Issue 3, 2013, Pages 175-181

  Shkolnikova, Julia ^a   Flynn, Jennifer ^a   Choong, Peter ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Atypical fracture; Bisphosphonate; Stress fracture

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; FEMUR FRACTURE; HUMAN; INTRAMEDULLARY NAILING; MALE; OSTEOPOROSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTRAMEDULLARY; HUMANS; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84874788591     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/ans.12018     Document Type: Article

References (41)

1. Black D, Cummings SR, Karpf DB etal. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
2. Shane E, Burr D, Ebeling PR etal. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2010; 25: 2267-2294.
3. Park-Wyllie L, Mamdani MM, Juurlink DN etal. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-789.
4. Dell R, Greene D, Ott S etal. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. J. Bone Miner. Res. 2010; 25: supplement 1.
5. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010; 47: 169-180.
6. Odvina C, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 2005; 90: 1294-1301.
7. Capeci C, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. Am. 2009; 91: 2556-2561.
8. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J. Bone Joint Surg. Br. 2010; 92: 679-686.
9. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long- term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009; 32: 775-785.
10. Isaacs J, Shidiak L, Harris I, Szomor Z. Femoral insufficiency fractures associated with prolonged alendronate therapy. Clin. Orthop. Relat. Res. 2010; 468: 3384-3392.
11. Koh J, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J. Orthop. Trauma 2010; 24: 75-81.
12. Kwek E, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39: 224-231.
13. Goh S, Yang KY, Koh JS etal. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Br. 2007; 89: 349-353.
14. Egol KA, Park JH, Tejwani NC. Outcomes following displaced atypical fracture of the femur. AAOS: AAOS Now, March, 2012. [Cited 15 April 2012.] Available from URL: www.aaos.org/news/aaosnow/mar12/clinical11.asp
15. Schilcher J, Michaelsson K. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 2011; 364: 1728-1737.
16. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 2009; 24: 1095-1102.
17. Porrino J, Kohl CA, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am. J. Roentgenol. 2010; 194: 1061-1064.
18. Capeci C, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. Br. 2010; 91: 2556-2561.
19. Duda G, Schneider E, Chao EY. Internal forces and moments in the femur during walking. J. Biomech. 1997; 30: 933-941.
20. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J. Clin. Endocrinol. Metab. 2010; 95: 5258-5265.
21. Armamento-Villareal R, Napoli N, Diemer K etal. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif. Tissue Int. 2009; 85: 37-44.
22. Girgis C, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N. Engl. J. Med. 2010; 362: 1848-1849.
23. Glennon D. Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: a case series. Bone 2009; 44(Suppl): 77-78.
24. Lenart B, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 2008; 358: 1304-1306.
25. Neviaser A, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low- energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma 2008; 22: 346-350.
26. Odvina C, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin. Endocrinol. (Oxf.) 2010; 72: 161-168.
27. Wang K, Moaveni A, Dowrick A, Liew S. Alendronate-associated femoral insufficiency fractures and femoral stress reactions. J. Orthop. Surg. (Hong Kong) 2011; 19: 89-92.
28. Black M, Schwartz AV, Ensrud KE etal. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 2006; 296: 2927-2938.
29. Watts N, Diab D. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 2010; 95: 1-11.
30. Lenart B, Neviasr AS, Lyman S etal. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case-control study. Osteoporos. Int. 2009; 20: 1353-1362.
31. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos. Int. 2010; 22: 993-1001.
32. Allen M, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 2007; 22: 1759-1765.
33. Allen M, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39: 872-879.
34. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000; 27: 13-20.
35. Komatsubara S, Mori S, Mashiba T etal. Effects suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J. Bone Miner. Res. 2004; 19: 999-1005.
36. Li, J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif. Tissue Int. 2001; 69: 281-286.
37. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-531.
38. Matheson G, Clement DB, Mckenzie DC, Taunton JE, Lloyd-Smith DR, Macintyre JG. Stress fractures in athletes. A study of 320 cases. Am. J. Sports Med. 1987; 15: 46-58.
39. Tan S, Koh SB, Goh SK, Howe TS. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos. Int. 2011; 22: 2211-2212.
40. Ott SM. What is the optimal duration of bisphosphonate therapy? Cleve. Clin. J. Med. 2011; 78: 619-630.
41. Australian Government MA. Pharmaceutical Benefits Schedule Item Reports. Edition. [Cited 1 November 2011.] Available from URL: https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml